Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
Status:
Completed
Trial end date:
2020-03-16
Target enrollment:
Participant gender:
Summary
This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study
in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.